This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Investors Twice Shy on Cell Therapeutics

Punk Ziegel biotech analyst Matt Kaplan believes that the Stellar 3 delay does suggest that positive data are coming. He combed medical journals and found 10 studies involving similar lung cancer patients with performance status 2 who were treated with various combinations of chemotherapy drugs. In these studies, median survival fell typically into the four-to-five month range.

The last patient enrolled in the Stellar 3 trial in November 2003, so given an anticipated early 2005 data release, Kaplan believes this suggests that Xyotax is having a positive impact on survival. Kaplan rates Cell Therapeutics a buy with an $18 price target. His firm has a banking relationship with the company.

But yet, investors haven't responded at all. The stock is actually down from when Cell Therapeutics first started dropping bullish hints about Stellar 3 in May.

"My guess from an investor standpoint is that in the absence of any near-term data, investors are not willing to give Cell Therapeutics the benefit of the doubt, especially when management has a history of disappointing," said Lehman Brothers analyst Jim Birchenough.

The biggest disappointment so far, he says, is the company's failure to follow through on a much-hyped promise to ink a Big Pharma marketing partnership for Xyotax. Birchenough downgraded Cell Therapeutics to equal weight from overweight in June 2003, when instead of announcing an expected Xyotax deal, the company ventured over to Europe to acquire Novuspharma, a rather obscure Italian biotech firm that had been on the sale block for months, with no takers. (Birchenough's firm doesn't do banking for Cell Therapeutics.)

Indeed, a look at Cell Therapeutics' chart shows that its stock hit the skids the day the Novuspharma acquisition was announced on June 17, 2003. The previous day, the stock hit an intraday high of $15.70 -- it hasn't been anywhere close to that since.

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs